177 related articles for article (PubMed ID: 7969825)
1. Prognostic significance of bromodeoxyuridine labeling in primary and recurrent glioblastoma multiforme.
Ritter AM; Sawaya R; Hess KR; Levin VA; Bruner JM
Neurosurgery; 1994 Aug; 35(2):192-8; discussion 198. PubMed ID: 7969825
[TBL] [Abstract][Full Text] [Related]
2. Predicting the recurrence of ependymomas from the bromodeoxyuridine labeling index.
Asai A; Hoshino T; Edwards MS; Davis RL
Childs Nerv Syst; 1992 Aug; 8(5):273-8. PubMed ID: 1394266
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling.
Hoshino T; Ahn D; Prados MD; Lamborn K; Wilson CB
Int J Cancer; 1993 Feb; 53(4):550-5. PubMed ID: 8382191
[TBL] [Abstract][Full Text] [Related]
4. Prognostic implications of the bromodeoxyuridine labeling index of human gliomas.
Hoshino T; Prados M; Wilson CB; Cho KG; Lee KS; Davis RL
J Neurosurg; 1989 Sep; 71(3):335-41. PubMed ID: 2549222
[TBL] [Abstract][Full Text] [Related]
5. Meningiomas: clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling.
Shibuya M; Hoshino T; Ito S; Wacker MR; Prados MD; Davis RL; Wilson CB
Neurosurgery; 1992 Apr; 30(4):494-7; discussion 497-8. PubMed ID: 1584346
[TBL] [Abstract][Full Text] [Related]
6. Enhancing tumor apparent diffusion coefficient histogram skewness stratifies the postoperative survival in recurrent glioblastoma multiforme patients undergoing salvage surgery.
Zolal A; Juratli TA; Linn J; Podlesek D; Sitoci Ficici KH; Kitzler HH; Schackert G; Sobottka SB; Rieger B; Krex D
J Neurooncol; 2016 May; 127(3):551-7. PubMed ID: 26830088
[TBL] [Abstract][Full Text] [Related]
7. Reoperation for Recurrent Glioblastoma and Its Association With Survival Benefit.
Tully PA; Gogos AJ; Love C; Liew D; Drummond KJ; Morokoff AP
Neurosurgery; 2016 Nov; 79(5):678-689. PubMed ID: 27409404
[TBL] [Abstract][Full Text] [Related]
8. Correlation between bromodeoxyuridine-labeling indices and patient prognosis in cerebral astrocytic tumors of adults.
Fujimaki T; Matsutani M; Nakamura O; Asai A; Funada N; Koike M; Segawa H; Aritake K; Fukushima T; Houjo S
Cancer; 1991 Mar; 67(6):1629-34. PubMed ID: 2001552
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implications of the proliferative potential of low-grade astrocytomas.
Hoshino T; Rodriguez LA; Cho KG; Lee KS; Wilson CB; Edwards MS; Levin VA; Davis RL
J Neurosurg; 1988 Dec; 69(6):839-42. PubMed ID: 3193189
[TBL] [Abstract][Full Text] [Related]
10. Proliferative characteristics of juvenile pilocytic astrocytomas determined by bromodeoxyuridine labeling.
Ito S; Hoshino T; Shibuya M; Prados MD; Edwards MS; Davis RL
Neurosurgery; 1992 Sep; 31(3):413-8; discussion 419. PubMed ID: 1407423
[TBL] [Abstract][Full Text] [Related]
11. Final report on the University of California-San Francisco experience with bromodeoxyuridine labeling index as a prognostic factor for the survival of glioma patients.
Lamborn KR; Prados MD; Kaplan SB; Davis RL
Cancer; 1999 Feb; 85(4):925-35. PubMed ID: 10091772
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms.
Kondziolka D; Flickinger JC; Bissonette DJ; Bozik M; Lunsford LD
Neurosurgery; 1997 Oct; 41(4):776-83; discussion 783-5. PubMed ID: 9316038
[TBL] [Abstract][Full Text] [Related]
13. Variability in the proliferative potential of human gliomas.
Hoshino T; Nagashima T; Cho KG; Davis RL; Donegan J; Slusarz M; Wilson CB
J Neurooncol; 1989 Jul; 7(2):137-43. PubMed ID: 2550593
[TBL] [Abstract][Full Text] [Related]
14. γ knife surgery versus reoperation for recurrent glioblastoma multiforme.
Skeie BS; Enger PØ; Brøgger J; Ganz JC; Thorsen F; Heggdal JI; Pedersen PH
World Neurosurg; 2012 Dec; 78(6):658-69. PubMed ID: 22484078
[TBL] [Abstract][Full Text] [Related]
15. Proliferative potential and prognostic evaluation of low-grade astrocytomas.
Ito S; Chandler KL; Prados MD; Lamborn K; Wynne J; Malec MK; Wilson CB; Davis RL; Hoshino T
J Neurooncol; 1994; 19(1):1-9. PubMed ID: 7815099
[TBL] [Abstract][Full Text] [Related]
16. Correlation of histopathological features and proliferative potential of gliomas.
Germano IM; Ito M; Cho KG; Hoshino T; Davis RL; Wilson CB
J Neurosurg; 1989 May; 70(5):701-6. PubMed ID: 2709110
[TBL] [Abstract][Full Text] [Related]
17. Proliferative potential of brain metastases.
Cho KG; Hoshino T; Pitts LH; Nomura K; Shimosato Y
Cancer; 1988 Aug; 62(3):512-5. PubMed ID: 3390791
[TBL] [Abstract][Full Text] [Related]
18. Resection of recurrent glioblastoma multiforme in elderly patients: a pseudo-randomized analysis revealed clinical benefit.
Fariña Nuñez MT; Franco P; Cipriani D; Neidert N; Behringer SP; Mader I; Delev D; Fung C; Beck J; Sankowski R; Nicolay NH; Heiland DH; Schnell O
J Neurooncol; 2020 Jan; 146(2):381-387. PubMed ID: 31933259
[TBL] [Abstract][Full Text] [Related]
19. Markers of cell division cycle in glioblastoma: significance in prediction of treatment response and patient prognosis.
Yousaf J; Hills C; Dixit S; Achawal S; O'Brien D; Greenman J; Scott IS
Br J Neurosurg; 2013 Dec; 27(6):752-8. PubMed ID: 23477614
[TBL] [Abstract][Full Text] [Related]
20. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.
Suchorska B; Weller M; Tabatabai G; Senft C; Hau P; Sabel MC; Herrlinger U; Ketter R; Schlegel U; Marosi C; Reifenberger G; Wick W; Tonn JC; Wirsching HG
Neuro Oncol; 2016 Apr; 18(4):549-56. PubMed ID: 26823503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
